Skystar Bio Pharmaceutical Company reported unaudited consolidated earnings results for the first quarter ended March 31, 2012. For the quarter, the company reported net revenue of $7,926,337 against $7,086,954 for the same period last year. Income from operation was $2,467,974 against $1,643,934 for the same period last year. Income before provision for income taxes was $2,373,722 against $2,409,282 for the same period last year. Net income was $1,904,754 or $0.26 per diluted share against $1,931,832 or $0.27 per diluted share for the same period last year. Net cash provided by operating activities was $2,021,671 against net cash used in operating activities of $6,288,315 for the same period last year. Purchases of plant and equipment were $54,965 against $22,275 for the same period last year. The company reiterated earnings guidance for the fiscal year 2012. The company expects fiscal year 2012 revenue guidance to be in the range of $53 million to $57 million for the full year.